Why Pfizer Stock Tumbled on Tuesday

By Eric Volkman – Updated Apr 7, 2026 at 4:19PM ESTKey PointsHe continues to consider Pfizer a sell.The pundit's main concern is the company's weaknesses in three key products.On the second trading day of the week, Pfizer (PFE +1.38%) was a laggard on the stock exchange. An analyst reiterated his bearish view of the stock, and more than a few investors were obviously convinced by the argument. That pushed the shares down by more than 2% that market session. Continued underperformance expected The pundit behind the new Pfizer note was RBC Capital's Trung Huynh. Before market open, he published an update centered on his underperform (sell, in other words) recommendation and $25 per share price target. Image source: Getty Images. Huynh's latest analysis of the pharmaceutical giant comes less than a month before the company is scheduled to publish its first-quarter earnings. According to reports, the analyst expects Pfizer's revenue for the period to fall 4% year over year. This will be due mainly to dynamics in three major products, in his opinion. These are the Covid drug Paxlovid, Vyndamax, a treatment for the rare, progressive heart disorder ATTR-CM, and the Pneumococcus vaccine Prevnar. Huynh wrote that competitive pressures have pushed Vyndamax's net realized prices down for six consecutive quarters. ExpandNYSE: PFEPfizerToday's Change(1.38%) $0.38Current Price$27.48Key Data PointsMarket Cap$156BDay's Range$26.97 - $27.4852wk Range$21.09 - $28.75Volume937Avg Vol45MGross Margin66.23%Dividend Yield6.26% A bargain at this price Pfizer is an out-of-favor pharmaceutical stock these days, as many investors remember the company's glory days earlier this decade as the co-developer of the widely consumed Covid vaccine Comirnaty. It's been retrenching since then through both proprietary drug development and the acquisition of promising pharma assets. However, it hasn't yet scored a knockout win with a major new product and is facing patent cliffs with some top drugs in the coming years. To me, this makes it something of a sleeping giant. That pipeline is very wide and varied, and, as it has in the past, I'm certain the company will bring a popular medicine to market before long. Meanwhile, the stock looks unsustainably cheap and it pays a very generous dividend. I'd disagree with Huynh's downbeat assessment.Read NextApr 7, 2026 •By David Jagielski, CPAPrediction: In 5 Years, You'll Wish You Bought Pfizer Stock TodayApr 3, 2026 •By Matt DiLallo20 Best High-Yield Dividend Stocks to Buy in 2026Mar 31, 2026 •By Jeremy BowmanWho Owns ChatGPT? Largest Shareholders & Board of DirectorsMar 29, 2026 •By Reuben Gregg BrewerPrediction: Buying Pfizer Stock Today Could Set You Up for LifeMar 25, 2026 •By Prosper Junior BakinyIs Pfizer Stock a Buy After This Win?Mar 23, 2026 •By David Jagielski, CPAPfizer Stock Is Doing Something It Hasn't Done Since 2022About the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedPfizerNYSE: PFE$27.47(+1.36%)+$0.37*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.